SCHEMBL4417883

SCHEMBL4417883

CCCCCCN1CC2C(CNc3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 3/20 0.41
HTT P42858 1/20 0.39
USP30 Q70CQ3 1/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 1/20 0.39
MAOA P21397 2/20 0.38
LMNA P02545 1/20 0.38
PTGS1 P23219 1/20 0.38
CALML3 P27482 1/20 0.38
SDHA P31040 1/20 0.38
S1PR1 P21453 1/20 0.38
KMT2A Q03164 1/20 0.38
GAA P10253 2/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
RET P07949 1/20 0.36
ROS1 P08922 1/20 0.36
FLT3 P36888 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179233 0.85 MAOB (0.41) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL2181891 0.85 POLB (0.46) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL2230043 0.83 L3MBTL1 (0.44) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL4412123 0.82 L3MBTL1 (0.41) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL4427710 0.82 NPC1 (0.45) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL4417879 0.82 L3MBTL1 (0.52) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL4422515 0.81 L3MBTL1 (0.40) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL4414984 0.81 MMP1 (0.44) MAOBNPC1MAOALMNAKMT2A
SCHEMBL2170676 0.80 LMNA (0.44) MAOBL3MBTL1NPC1HTTUSP30
SCHEMBL4417488 0.80 L3MBTL1 (0.41) MAOBL3MBTL1NPC1HTTUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MAOB 307/4885L3MBTL1 1416/4885NPC1 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.